Poxel doubles down on NASH with acquisition of DRX-065

30 August 2018

Marking its third major corporate transaction in 2018, metabolic disease biotech firm Poxel (Euronext: POXEL) today announced the strategic acquisition of privately-held US firm DeuteRx’ novel clinical stage product candidate, DRX-065 that Poxel plans to develop for the treatment of non-alcoholic steatohepatitis (NASH).

In addition, France-based Poxel also gains access to a portfolio of other deuterated drug candidates for metabolic, specialty and rare diseases. The transaction accentuates Poxel’s upward trajectory as the company’s diversified, mid- to late-stage pipeline remains well-positioned to target large market opportunities (ie, type 2 diabetes) and has the capability and expertise to advance earlier-stage metabolic programs currently in development.

Terms of the deal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK